Narrative review / 2017
A review notes trial differences may explain conflicting findings on niacin's cardiovascular benefits.
Niacin has been used for primary and secondary coronary heart disease prevention for over 40 years. Earlier clinical trials consistently demonstrated reductions in clinical events and lesion improvement, including an absolute mortality reduction of ≥6%, whereas two large trials in 2011 and 2014 found niacin added to statin therapy did not provide clinical event benefit over statin alone. The review identifies differences between earlier and recent trials regarding dyslipidemia types, niacin formulation, dosing, and timing. It notes that the population that benefits most can be defined by elevated low-density lipoprotein cholesterol and triglycerides alongside reduced high-density lipoprotein cholesterol, and states mealtime dosing, as opposed to bedtime dosing, may avoid a counter-regulatory hormone response.
- Study type
- Narrative review
- Who was studied
- Patients in coronary heart disease prevention trials
- What was measured
- Coronary heart disease clinical events and mortality
THE PAPER
Niacin and heart disease prevention: Engraving its tombstone is a mistake.
Superko HR, Zhao XQ, Hodis HN, Guyton JR. J Clin Lipidol, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.